BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Miles of milestones

...GvHD) Submit BLA YE12 Pfizer Inc. (NYSE:PFE) Tofacitinib RA PDUFA date August Pharming Group N.V. (Euronext:PHARM)/Hyupjin Corp....
BioCentury | Apr 2, 2012
Company News

Hyupjin, Pharming sales and marketing update

...Pharming granted Hyupjin commercialization rights to Ruconest conestat alfa in Korea to treat acute attacks of...
...rights to Ruconest conestat alfa in Korea to treat acute attacks of hereditary angioedema (HAE). Hyupjin...
...Pte. Ltd. (Singapore) has commercialization rights in Brunei, Indonesia, Malaysia, the Philippines, Singapore and Thailand. Hyupjin Corp....
Items per page:
1 - 3 of 3
BioCentury | Jan 7, 2013
Finance

Buyside View XXI: Sunny side up

Stephen Hansen Senior Writer A strong crop of early PDUFA dates and a sense that FDA is more navigable have given money managers in the U.S. and Europe a positive outlook for 2013, which they...
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Miles of milestones

...GvHD) Submit BLA YE12 Pfizer Inc. (NYSE:PFE) Tofacitinib RA PDUFA date August Pharming Group N.V. (Euronext:PHARM)/Hyupjin Corp....
BioCentury | Apr 2, 2012
Company News

Hyupjin, Pharming sales and marketing update

...Pharming granted Hyupjin commercialization rights to Ruconest conestat alfa in Korea to treat acute attacks of...
...rights to Ruconest conestat alfa in Korea to treat acute attacks of hereditary angioedema (HAE). Hyupjin...
...Pte. Ltd. (Singapore) has commercialization rights in Brunei, Indonesia, Malaysia, the Philippines, Singapore and Thailand. Hyupjin Corp....
Items per page:
1 - 3 of 3